Capitol Health Limited’s Share Price remained Flat after acquiring 9 Clinics

Capitol Health Limited (ASX: CAJ) is a provider of diagnostic imaging services like x-ray, ultrasound, Doppler, CT scan, Cone beam CT, computer tomography etc. The company provides its services to healthcare markets in Australia. Currently, the company is operating clinics in Victoria and New South Wales.

On 18 September 2018, the company announced that it has acquired 3 clinics in Melbourne and 6 clinics in Perth. These acquisitions are a part of the strategic step in the company’s existing growth strategy. The clinics acquired in Perth are covering a substantial part of the metropolitan area. These include Integrated Radiology, Booragoon Radiology, Ellenbrook Radiology, Forrestfield Radiology, Quinns Medical Imaging and Image central. With additional capital investment and targeted recruitment these acquisitions can help the business to grow. These independent clinics are acquired from 4 different vendors which could help the company to derive network benefits from the clinics. It is expected that these new acquisitions can contribute up to $16.5 million in revenue and $3.1 million in EBITDA in FY 2019.

This move thus marks the beginning of setting a footprint in Perth, which looks to be quite an attractive opportunity for the group. Primarily, the group has estimated that the new clinics may contribute $ 16.5 million in terms of revenue with $ 3.1 million in terms of EBITDA for CAJ on a yearly basis. This has been at the back of estimations done through FY19 forecast. 

In a way, the group says that the estimations reflect EBITDA multiple of 5.5 x moving up to 6.5 x, subject to meeting respective earn out conditions. The group thus aims to report a strong full year FY 19 performance as the acquisitions will be completed and included in the FY 19 guidance. On the other hand, the group is progressing well on its buy-back program. The group has reported a solid 10% growth in operating revenue for FY18 and reported underlying EBITDA growth of 9%. Its acquisitions have been as per the strategic moves and find support from balance sheet strength. At the same time, the group is catering to cost reduction management and is also enhancing clinical governance.

On 18 September 2018, the share price of Capitol traded flat with intraday trading of 56690 shares. CAJ’s share was at $0.280 at a market capitalization of 225.67m as on 18 September 2018 (AEST 1:22 PM).

Dividend Stocks To Buy

Sponsored ad by Kalkine

The Income available from dividends remains attractive for many investors.

We take a look at the best yields on the market and assess what they say about a company’s prospect.

One Thing is certain, though, Australia interest rates are still low, making income difficult to come by and keeping the focus for many investors on high yielding stocks. Kalkine’s team of analysts bought you handpicked report for “Top 25 Dividend Stocks For 2018.”

ASX-relevant Special Reports are published year-round to provide a detailed analysis into an investing opportunity or a potential risk to your portfolio.

Click here to get your free report.


Disclaimer

The advice given by Kalkine Pty Ltd and provided on this website is general information only and it does not take into account your investment objectives, financial situation or needs. You should therefore consider whether the advice is appropriate to your investment objectives, financial situation and needs before acting upon it. You should seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) as necessary before acting on any advice. Not all investments are appropriate for all people. Kalkinemedia.com and associated websites are published by Kalkine Pty Ltd ABN 34 154 808 312 (Australian Financial Services License Number 425376). website), employees and/or associates of Kalkine Pty Ltd do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations.

Facebook Comments

Join Our Discussion

Start discussion with value Investors for ASX Stock Market Investment and Opinion.


6 Cannabis Stocks under Investor’s Limelight…

Cannabis companies that sell both medicinal weed and recreational pot. Marijuana stocks to look at. Marijuana mergers and acquisitions. Dispensary data analytics. Upcoming marijuana IPO’s Those phrases have become increasingly common as marijuana legalization spreads.

Global spending on legal cannabis is expected to grow 230% to $32 billion in 2020 as compared to $9.5 in 2017, according to Arcview Market Research and BDS Analytics. As of June 29, 2018 the United States Marijuana Index, despite a lot of uncertainty around regulations, has over the past 1 year gained 71.49%, as compared to about 12% gain seen by the S&P 500.

Click here for your FREE Report

LEAVE A REPLY

Please enter your comment!
Please enter your name here